N/A
Completed N=41
The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study
Source: ClinicalTrials.gov NCT01691781 ↗Enrolled (actual)
41
Serious AEs
0.0%
Results posted
Aug 2017
Primary outcomePrimary: Parathyroid Hormone Following 1 Week of ACE Inhibitor Administration — 70.9; 32.5 pg/mL — p=0.049
Summary
This study will evaluate whether commonly used blood pressure medications called "ACE inhibitors" can lower parathyroid hormone.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Parathyroid Hormone Following 1 Week of ACE Inhibitor Administration |
70.9; 32.5 | 0.049 sig |
| SECONDARY Urinary Aldosterone Excretion Measurements Following 1 Week of ACE Inhibitor Therapy |
7.8; 6.1 | 0.22 |
| SECONDARY Serum Calcium Following 1 Week of ACE Inhibitor Administration |
10.5; 9.5 | 0.48 |
Eligibility Criteria
Inclusion Criteria
- Healthy subjects with with no medical problems (n=15) and individuals with primary hyperparathyroidism (n=30)
- normal blood pressure or stage 1 hypertension that is either untreated, or adequately treated with a single anti-hypertensive medication.
- Age >18 years and 60ml/min
Exclusion Criteria
- Chronic Kidney Disease or eGFR 7.5%
- History of liver failure
- History of heart failure
- The use of typical or atypical antipsychotic medications or lithium.
- Chronic inflammatory conditions (such as inflammatory bowel disease or arthritis) that are treated with prescribed doses of NSAIDs or glucocorticoids
- The use of prescribed doses of potassium supplements.
- Illness requiring overnight hospitalization in the past 6 months
- Active tobacco or recreational drug use
- Pregnancy or current breast feeding
Data sourced from ClinicalTrials.gov (NCT01691781). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.